Association of prostate cancer risk with insulin, glucose, and anthropometry in the baltimore longitudinal study of aging

Urology

Volumn 63, Issue 2, 2004, Pages 253-258

  Hubbard, J Slade ^a   Rohrmann, Sabine ^c   Landis, Patricia K ^c   Metter, E Jeffrey ^c   Muller, Denis C ^c   Andres, Reubin ^c   Carter, H Ballentine ^b   Platz, Elizabeth A ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AGING; ANTHROPOMETRY; ARTICLE; BODY MASS; CANCER RISK; EVALUATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 1242341931     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.09.060     Document Type: Article

References (30)

1. Boyle P., Maisonneuve P., Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology. 46:(suppl 3A):1995;47-55.
2. Schulman C.C., Ekane S., Zlotta A.R. Nutrition and prostate cancer evidence or suspicion? Urology. 58:2001;318-334.
3. Chan J.M., Stampfer M.J., Giovannucci E.L. What causes prostate cancer? A brief summary of the epidemiology. Cancer Biol. 8:1998;263-273.
4. Hsieh LJ, Carter HB, Landis PK, et al: Association of energy intake with prostate cancer in a long term aging study: the Baltimore Longitudinal Study of Aging (United States). Urology 61: 297-301, 2003.
5. Hsing A.W., Chua S., Gao Y., et al. Prostate cancer risk and serum levels of insulin and leptin a population-based study . J Natl Cancer Inst. 93:2001;783-791.
6. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition. 13:1997;795-803.
7. Dahle S.E., Chokkalingam A.P., Gao Y., et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 168:2002;599-604.
8. Kaaks R., Lukanova A. Energy balance and cancer the role of insulin and insulin-like growth factor-I . Proc Nutr Soc. 60:2001;91-106.
9. Sinha R., Fisch G., Teague B., et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med. 346:2002;802-810.
10. Shock NW, Greulich RC, Andres R, et al: Normal Human Aging: The Baltimore Longitudinal Study of Aging. NIH Publication No. 84-2450. Washington, DC, U.S. Government Printing Office, November 1984.
11. Muller D.C., Elahi D., Tobin J.D., et al. Insulin response during the oral glucose tolerance test the role of age, sex, body fat and the pattern of fat distribution . Aging Clin Exp Res. 8:1996;13-21.
12. Fang J., Metter E.J., Landis P., et al. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mL. Urology. 59:2002;889-894.
13. Carter H.B. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer the only rational approach for men 50 years old and older . Urology. 55:2000;796-799.
14. Standardization of the oral glucose tolerance test. Diabetes. 18:1969;299-307.
15. Soeldner J.S., Slone D. Critical variables in the radioimmunoassay of serum insulin using the double antibody technique. Diabetes. 14:1965;771-779.
16. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man . Diabetologia. 28:1985;412-419.
17. Kleinbaum D.G., Morgenstern H., Kupper L.L. Epidemiologic Research Principles and Quantitative Methods . 1982;John Wiley & Sons, New York. pp 464-468.
18. Stattin P., Soderberg S., Hallmans G., et al. Leptin is associated with increased prostate cancer risk a nested case-referent study . J Clin Endocrinol Metab. 86:2001;1341-1345.
19. Zumoff B. Hormonal abnormalities in obesity. Acta Med Scand. 723:(suppl):1988;153-160.
20. Gapstur S.M., Gann P.H., Colangelo L.A., et al. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control. 12:2001;763-772.
21. Singh G., Lakkis C.L., Laucirica R., et al. Regulation of prostate cancer cell division by glucose. J Cell Physiol. 180:1999;431-438.
22. Tulinius H., Sigfusson N., Sigvaldason H., et al. Risk factors for malignant diseases a cohort study on a population of 22,946 Icelanders . Cancer Epidemiol Biomarkers Prev. 6:1997;863-873.
23. Davey-Smith G., Egger M., Shipley M.J., et al. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol. 136:1992;1110-1114.
24. Thompson M.M., Garland C., Barrett-Connor E., et al. Heart disease risk factors, diabetes and prostatic cancer in an adult community. Am J Epidemiol. 129:1989;511-517.
25. Lean M.E.J., Han T.S., Seidell J.C. Impairment of health and quality of life in people with large waist circumference. Lancet. 351:1998;853-856.
26. Giovannucci E., Rimm E.B., Stampfer M.J., et al. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 6:1997;557-563.
27. Hsing A.W., Deng J., Sesterhenn I.A., et al. Body size and prostate cancer a population-based case-control study in China . Cancer Epidemiol Biomarkers Prev. 9:2000;1335-1341.
28. Demark-Wahnefried W., Conaway M.R., Robertson C.N., et al. Anthropometric risk factors for prostate cancer. Nutr Cancer. 28:1997;302-307.
29. Lee I., Sesso H.D., Paffenbarger R.S. A prospective cohort study of physical activity and body size in relation to prostate cancer risk (United States). Cancer Causes Control. 12:2001;187-193.
30. Whittemore A.S., Kolonel L.N., Wu A.H., et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 87:1995;652-661.